UK Explains How To Build COVID-19 Resilience Into Trial Design
Sponsors Can Use Existing Regulatory Flexibilities To Minimize Further Disruptions
Executive Summary
The UK Medicines and Healthcare products Regulatory Agency wants clinical trial sponsors to integrate available regulatory flexibilities into normal practice so that their studies can withstand further potential disruptions from the COVID-19 pandemic.